CELG News and Press, Celgene Corporation From 07/12/19

My plan for my investment in NantKwest ( NK ) was to build a conservative position in anticipation that the market will start to identify the prospective upside in the stock. Indeed, NantKwest still has a couple of years from a potential product launch. Still, I expect CEO and founder Dr. Soon...

Editor's note: Seeking Alpha is proud to welcome PylBio Investment as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to SA Essential. Click here to find out more » Welcome to ou...

AbbVie ( ABBV ) had entered into a deal to acquire Allergan ( AGN ) for $63 billion, which would be $188 a share in cash and stock. This was a huge premium of 45% over the closing price of $129.57 on Monday, June 25, 2019. AbbVie's stock tanked on this news, closing lower by 16%. In my...

Bristol-Myers Squibb ( BMY ) started 2019 by announcing it would acquire Celgene ( CELG ). The combination will create what will be one of the broadest sets of drugs that are both approved and/or in a pipeline. The combination of these companies will likely have better than appreciated cash ...

Bristol-Myers Squibb Co. ( BMY ) disclosed that it needs to dispose of Celgene’s ( CELG ) Otezla to address US Federal Trade Commission ((FTC)) fears over the possibility of BMY/CELG dominating in the psoriasis space. As a result, the BMY/CELG merger finalization is expected to be pushe...

By Andy Acker, CFA Global Life Sciences Portfolio Manager Andy Acker discusses how large-cap biopharmaceutical companies utilize M&A strategies to fill product pipelines and maintain steady cash flows. Transcript Andy Acker : Earlier this week, AbbVie ([[ABBV]])...

Merger activity went on a tear last week with twelve new deals announced and one pending deal closing. Deal Statistics: New Deals: The acquisition of Caesars Entertainment Corporation (CZR) by Eldorado Resorts (ERI) for $17.3 billion in a cash plus stock deal. Under the terms of...

AnaptysBio ( ANAB ) stock closed lower by 11% on Friday after a rival drug known as REGN3500 from Regeneron Pharmaceuticals ( REGN ) and its partner Sanofi ( SNY ), failed a mid-stage study in asthma . I believe that despite a rival failing with a similar drug, AnaptysBio's stock should...

AbbVie Inc. (ABBV) has reached a deal with Allergan (AGN) for about $188 per share in cash and stock. Allergan shareholders get $120 in cash and 17% of the combined company (the value of that is in flux, so take the numbers with a grain of salt). This implies there is still a very widespread o...

Mergers is the sign of a healthy stock market AbbVie (ABBV) is buying the long-suffering Allergan (AGN) for 63 billion bucks. Long-term readers might remember me making a strong case to go long on AGN because of the charts, and then Carl Icahn got involved, so we were able to escape with som...